Cargando…

Effect of Rifabutin in Dolutegravir Dosing: A Case Series

Background: Tuberculosis (TB) is the leading cause of death in human immunodeficiency virus (HIV)-infected people worldwide. Currently there are no studies examining the use of Rifabutin (RBN) and Dolutegravir (DTG) in co-infected persons. This is a case series of 4 co-infected patients receiving bo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mendoza, Maria A., Alshaer, Mohammad H., Roldan, Giovanni, Castro, Jose Guillermo, Ashkin, David, Peloquin, Charles A., Boulanger, Catherine V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421219/ https://www.ncbi.nlm.nih.gov/pubmed/36026587 http://dx.doi.org/10.1177/23259582221111077

Ejemplares similares

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

Rifabutin Use in Staphylococcus Biofilm Infections: A Case Series
por: Doub, James B., et al.
Publicado: (2020)

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections
por: Monk, Miranda, et al.
Publicado: (2022)

Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study
por: Palacios, Rosario, et al.
Publicado: (2018)

Dolutegravir-Based Antiretroviral Regimens for HIV Liver Transplant Patients in Real-Life Settings
por: Cattaneo, Dario, et al.
Publicado: (2020)

Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir
por: Moultrie, Harry, et al.
Publicado: (2015)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
por: Mehta, Rashmi, et al.
Publicado: (2020)

Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
por: Tan, M, et al.
Publicado: (2019)

793. Rifabutin Use in Staphylococcal Prosthetic Material Infections: A Case Series
por: Monk, Miranda, et al.
Publicado: (2021)

2354. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for rifampin-resistant or treatment-intolerant TB disease
por: Haley, Connie A, et al.
Publicado: (2022)

Concomitant Treatment of Tuberculosis and Hepatitis C Virus in Coinfected Patients Using Serum Drug Concentration Monitoring
por: Ashkin, Alex, et al.
Publicado: (2023)

Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor‐ to dolutegravir‐based antiretroviral therapy: A prospective cohort study in Lesotho (DO‐REAL study)
por: Brown, Jennifer A., et al.
Publicado: (2021)

Regorafenib adjusted dose for Chilean patients with chemoresistant metastatic colorectal cancer: a case series
por: Leal, José Luis, et al.
Publicado: (2018)

Rifabutin Is Active against Mycobacterium abscessus Complex
por: Aziz, Dinah Binte, et al.
Publicado: (2017)

Rifabutin Is Active against Mycobacterium abscessus in Mice
por: Dick, Thomas, et al.
Publicado: (2020)

Safety of Rifabutin in patients with rifampicin-induced thrombocytopenia
por: Sarkar, Trina, et al.
Publicado: (2020)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

Pharmacology, Dosing, and Side Effects of Rifabutin as a Possible Therapy for Antibiotic-Resistant Acinetobacter Infections
por: Phillips, Matthew C, et al.
Publicado: (2020)

Effect of carbamazepine on dolutegravir pharmacokinetics and dosing recommendation
por: Song, Ivy, et al.
Publicado: (2016)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Ex Vivo Human Placental Transfer of Rifampin and Rifabutin
por: Magee, Kevin P., et al.
Publicado: (1996)

Bilateral uveitis associated with concurrent administration of rifabutin and nelfinavir
por: Cheng, Wen-Hsin, et al.
Publicado: (2015)

Tuberculosis-HIV treatment with rifampicin or rifabutin: are the outcomes different?
por: Schmaltz, Carolina Arana Stanis, et al.
Publicado: (2019)

Rifabutin for the Treatment of Helicobacter pylori Infection: A Review
por: Gisbert, Javier P.
Publicado: (2020)

Comments regarding use of rifabutin for Helicobacter pylori eradication
por: Graham, David Y.
Publicado: (2021)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

Combining Low-Dose Rituximab and Bortezomib as Immunosuppressive Therapy for Acquired Hemophilia A: 6 Case Series
por: Fu, Yuhan, et al.
Publicado: (2023)

Impaired fasting glucose in breast cancer survivors of a general hospital at Mexico City: A case series study
por: Ortiz-Mendoza, Carlos Manuel
Publicado: (2019)

In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
por: Trebosc, Vincent, et al.
Publicado: (2020)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
por: Wolf, Eva, et al.
Publicado: (2021)

Recurrent neutropenia induced by rifabutin in a renal transplant recipient
por: Chang, Ji Yeun, et al.
Publicado: (2014)

Rifabutin: A Repurposing Candidate for Mycobacterium abscessus Lung Disease
por: Dick, Thomas
Publicado: (2020)

Rifabutin-Cobicistat Drug Interaction Resulting in Severe Bilateral Panuveitis
por: Toomey, Christopher B., et al.
Publicado: (2020)

Rifabutin as salvage therapy for Helicobacter pylori eradication: Cornerstones and novelties
por: Borraccino, Antonia Valeria, et al.
Publicado: (2022)

Successful Anticoagulation With Warfarin After Switching From Rifampin to Rifabutin
por: Alnewais, Marwah E., et al.
Publicado: (2023)

Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection
por: Navarro-Jarabo, José M, et al.
Publicado: (2007)

Correction: The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4b6h5fkn0fsc0ru24daklqk1gk